Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb comparison of antimalarial parasite-clearing regimens before PCR monitoring
PACTR201309000625311Phase 2Unknown
- Sponsor
- KEMRI-Wellcome Trust Research Programme
- Start
- Oct 2013
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of artesunate, atovaquone, proguanil, sulfadoxine, pyrimethamine and 1 more in malaria and Falciparum malaria (PF) (3 arms), sponsored by KEMRI-Wellcome Trust Research Programme. Primary endpoint: Time to first episode of Plasmodium falciparum infection. Status: unknown.
02
Drugs
artesunateatovaquoneproguanilsulfadoxinepyrimethamine
03
Conditions
malariaFalciparum malaria (PF)
Beyond the preview
Go deeper on PACTR201309000625311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201309000625311.